Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 3147Neoplasms 2478Carcinoma, Non-Small-Cell Lung 1889Prostatic Neoplasms 1645Colorectal Neoplasms 1438Lung Neoplasms 1312Multiple Myeloma 940Neoplasm Metastasis 930Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 862Ovarian Neoplasms 815Melanoma 794Carcinoma, Hepatocellular 745Stomach Neoplasms 650Brain Neoplasms 643Recurrence 642Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 613Glioblastoma 575Lymphoma 551Uterine Cervical Neoplasms 549Triple Negative Breast Neoplasms 515Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 505Endometrial Neoplasms 467Hematologic Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 448Sarcoma 439Lymphoma, Non-Hodgkin 439

Interventions

trastuzumab deruxtecan 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Cisplatin 2Capecitabine 2pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × 1 year × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06846996 2025-07-08

RECOVER

Daiichi Sankyo

Recruiting
260 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡